摘要
目的观察阿托伐他汀对扩张型心肌病(DCM)患者心室重构和心功能的影响,以及在心力衰竭患者中用药的安全性。方法选择66例DCM患者,随机分为干预组(31例)及对照组(35例),前者在常规治疗基础上合用阿托伐他汀10mg/d。于干预前及干预后1、3、6个月时,分别检测肝功能、肾功能、肌酸激酶(CK)及各项心功能指标。结果干预治疗前后比较,两组内CK指标均无明显改变,但肝功能指标均明显好转,差异有统计学意义(P<0.01);两组间同期比较差异无统计学意义(P>0.05)。两组内各项心功能指标均有明显改善,差异有统计学意义(P<0.01);两组间同期比较,干预组比对照组疗效更好,但差异无统计学意义(P>0.05)。结论阿托伐他汀治疗DCM有改善心功能、逆转心室重构及缩小心脏的趋势,但与对照相组比无统计学上的差异。阿托伐他汀10mg在DCM中应用是安全的。
Objective To determine the impact of atorvastatin on the cardiac function and ventricular remodeling in patients with dilated cardiomyopathy（ DCM）. Methods 66 DCM patients were randomized into atorvastatin group（ n = 31 ）and control group （n = 35 ）. Patients in atorvastatin group received atorvastatin 10 mg/d,while patient in control group only received standard care. Measured liver function, renal function, cardic kinase（CK） ,and cardiac function at baseline, month 1,3 and 6. Results There were no significant differences in CK between 2 treatment groups eithor at baseline or during the study period. Of note,live function was significant improved in two treatment groups when compared with baseline. But, there was no significant difference in liver function between 2 groups at month 1,3 and 6 （P 〉 0.05 ）. Regarding cardiac function, there was a significant improvement in 2 treatment group when compared with baseline, however there was only a trend favoring patients given atorvastatin as compared those given standard care （ P 〉 0.05 ）. Conclusion Atorvastatin （ 10 mg/ d） might improve cardiac function, reverse cardiac remodelling, however it needs to be confirmed in further clinical study with large sample size.
出处
《中国实用医药》
2008年第1期11-13,共3页
China Practical Medicine
